>중동 및 아프리카 제약용 부형제 시장, 기능별(결합제 및 접착제, 붕괴제, 코팅제, 착색제, 용해제, 향미료, 감미료, 희석제, 윤활제, 완충제, 유화제, 방부제 , 산화 방지제, 흡착제, 용매, 완화제 , 글리덴트, 킬레이트제, 소포제 및 기타), 투여 형태(고체, 반고체, 액체), 투여 경로(경구 부형제, 국소 부형제, 비경구 부형제, 기타 부형제), 최종 사용자(제약 및 생물 제약 회사, 계약 제형업체, 연구 기관 및 학계, 기타), 유통 채널(직접 입찰, 소매 판매, 기타), 업계 동향 및 2029년까지의 예측.
중동 및 아프리카 제약 보조제 시장 분석 및 통찰력
제약 부형제는 약물 제형 및 개발에 중요한 역할을 합니다. 이러한 물질에는 약리학적으로 활성인 약물 또는 전구약물 이외의 물질이 포함됩니다. 제약 부형제는 약물을 표적 부위로 효율적으로 전달합니다. 이러한 분자는 약물이 동화되고 약물 효능을 향상시키는 동안 너무 일찍 방출되는 것을 방지합니다. 일부 제약 부형제는 약물 통합을 촉진하여 혈류에서 약물 흡수를 증가시킵니다.
또한, 제약 부형제는 약물 식별에도 사용됩니다. 제약 부형제는 또한 약물 맛을 향상시키는 데 사용되어 환자의 순응도, 특히 어린이의 순응도를 높입니다. 제약 부형제의 화학적 특성에 따라 유기 및 무기 공급원에서 얻을 수 있습니다. 유기 화학 물질에는 탄수화물, 석유화학 제품 , 올레오케미컬 및 단백질 등이 있습니다. 제약 부형제는 결합제, 충전제, 희석제, 현탁제 또는 코팅제, 향미제, 붕해제, 착색제, 윤활제 및 활택제, 감미료 및 방부제 등으로 작용할 수 있습니다. 제약 부형제는 결합제 및 접착제, 붕해제, 가용화제, 향미제, 유화제, 방부제, 산화 방지제, 활택제 및 킬레이트 제를 포함하여 다양한 목적으로 사용되는 여러 가지 기능을 가지고 있습니다 .
그러나 약물과 부형제 승인에 대한 규제 엄격성이 높아지고, 비용과 시간이 많이 소요되는 약물 개발 과정이 이 시장의 성장을 제약할 것으로 예상됩니다.
Data Bridge Market Research analyzes that the Middle East & Africa pharmaceutical excipients market is expected to reach the value of USD 326.46 million by 2029, at a CAGR of 5.5% during the forecast period. Functionality accounts for the largest type segment in the market due to the rapid demand for IT solutions and services in the Middle East & Africa. This market report also covers pricing analysis, patent analysis, and technological advancements in depth.
Report Metric |
Details |
Forecast Period |
2022 to 2029 |
Base Year |
2021 |
Historic Years |
2020 (Customizable to 2019 - 2014) |
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
Segments Covered |
By Functionality (Binders And Adhesives, Disintegrants, Coating Material, Coloring Agents, Solubilizers, Flavors, Sweetening Agents, Diluents, Lubricants, Buffers, Emulsifying Agents, Preservatives, Antioxidants, Sorbents, Solvents, Emollients, Glidents, Chelating Agents, Antifoaming Agents, and Others), Dosage Form (Solid, Semi-Solid, Liquid), Route of Administration (Oral Excipients, Topical Excipients, Parenteral Excipients, Other Excipients), End User (Pharmaceutical and Biopharmaceutical Companies, Contract Formulators, Research Organization and Academics, Others), Distribution Channel (Direct Tender, Retail Sales, Others). |
Countries Covered |
South Africa, Saudi Arabia, UAE, Israel, Kuwait, Egypt, the Rest of the Middle East & Africa. |
Market Players Covered |
Kerry Group plc., DFE Pharma, Cargill, Incorporated, Pfanstiehl, Colorcon, MEGGLE GmbH & Co. KG, Omya AG, Peter Greven GmbH & Co. KG, Ashland., Evonik, Dow, Croda International Plc, Roquette Frères., The Lubrizol Corporation, BASF SE, Avantor, Inc., BENEO, Chemie Trade, among others. |
Middle East & Africa Pharmaceutical Excipients Market Definition
Pharmaceutical excipients involve everything in a drug except the active pharmaceutical ingredients. These molecules don’t possess medicinal properties and are ultimately used to enhance the drug's physiological absorption. Pharmaceutical excipients are inert in nature, allowing the drug molecule to apply to patients in the right form. Traditionally the pharmaceutical excipients were simple molecules, but technological innovation and increasing demand for novel drug delivery systems enhanced the pharmaceutical excipient's complexity. Pharmaceutical excipients promote the patient’s drug acceptability and boost the drug's stability and bioavailability.
Moreover, pharmaceutical excipients help maintain drug integrity, which helps in drug storage. Different pharmaceutical excipients are based on their chemical nature, including inorganic and organic chemicals. Organic chemicals include carbohydrates, petrochemicals, oleochemicals, and proteins, among others. Pharmaceutical excipients can act as binders, fillers, diluents, suspension or coating agents, flavoring agents, disintegrants, colorants, lubricants and glidants, sweeteners, and preservatives, among others.
The future of excipients science and technology has changed and continues to change. Better progress has been made in such areas as harmonizing excipient pharmacopeial monographs and applying new analytical methods to characterize excipients better.
Middle East & Africa Pharmaceutical Excipients Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Rise in Generic Drug Production and Uses
According to the U.S. Food and Drug Administration (U.S. Food and Drug Administration). FDA) and the National Center for Biotechnology Information (NCBI), a generic drug is a drug that has been created to look like an approved brand-name drug that is available in dosage form, with safety, strength, route of administration, quality, and performance. After the drug's patent expires, the cost savings associated with conventional drug use are not immediately apparent. Generic drugs, like brand-name drugs, require competition in the generic drug market before reducing costs; two to three years after the loss of exclusivity, the price of a generic drug is usually 60-70% lower than that of a brand-name drug. Since India has the highest per capita spending, these generic drugs will save a lot of money that can be used for other health problems. Nationally, the use of generic drugs has increased significantly in recent years. The fact that cheap substitutes for branded drugs are a major reason likely to spur the growth of the pharmaceutical industry. The generic drug industry in the near future.
Thus, increasing demand for generic drugs and rising production are expected to drive the Middle East & Africa pharmaceutical excipients market growth. Also, the cost of generic drugs is less, which increases the use of generic drugs.
- The Surge in Demand for Excipients
Pharmaceutical excipients are substances in pharmaceutical dosage forms not for direct therapeutic use but to facilitate the manufacture, protection, support, or improvement of stability and availability. With the increased development of the Middle East & Africa pharmaceutical industry, excipients also have a light part. Recently, there has been an increasing demand for generic drugs, which has led to an increase in the excipients demand. In addition, there has been a sharp increase in cases of chronic diseases.
Excipients are inert substances, other than pharmaceutically active drugs, introduced into the manufacturing process or included in the dosage form of pharmaceutical products. Excipients are widely used in drug formulations to add bulk to solid formulations, provide long-term stability, and facilitate drug absorption. Furthermore, it also improves the product's overall safety or functional properties during use or storage.
Thus, wide uses of excipients in drug formulation and applications of excipients are expected to drive the market of the Middle East & Africa pharmaceutical excipients.
Restraint
- Increasing Regulatory Stringency Regarding The Approval of Drugs and Excipients
Generic drug approval rules are largely the same worldwide, with little difference in developing countries. This is because he is not required to undergo bioequivalence (BE) study in this part of the world to obtain generic drug approval. Governments must ensure consistent quality of all generic drugs, medical experts say. Only then will doctors be happy and confident in prescribing generic drugs. A major reason for physicians' (and even patients') lack of confidence in generic drugs has been the lack of strict regulatory requirements regarding the number of generic drugs and the number of impurities allowed.
Controlling the manufacture and distribution of excipients is now considered a top priority by regulators and drug manufacturers, as mixing excipients has resulted in adverse patient events. Furthermore, with the emergence of new excipients and delivery systems, better control of the quality and supply of pharmaceutical excipients has become increasingly important in the context of in vivo activity. Recognizing the important role of excipients in pharmaceutical dosage forms requires excipient suppliers to meet the quality requirements of the pharmaceutical industry, and the pharmaceutical industry, in general, must work to ensure the product's safety. The integrity of use or storage in the supply chain. Hence, the increasing regulatory stringency regarding the approval of drugs and excipients is expected to restrain the Middle East & Africa pharmaceutical excipients market growth.
Opportunity
-
Strategic Initiatives by Market Players
The rise in the pharmaceutical excipients market increases the need for strategic business ideas. It includes a partnership, business expansion, and other development. The rising demand for pharmaceuticals is significantly increasing the demand for pharmaceutical excipients, and to cope with this demand, companies are building new manufacturing sites, among other strategic initiatives.
These strategic initiatives, such as product launches, acquisitions, agreements, and business expansion by the major market player, will boost the pharmaceutical excipients market growth and is expected to act as an opportunity for the Middle East & Africa pharmaceutical excipients market.
Challenge
- Associated Side Effects
Adverse effects due to pharmaceutical excipients in drug formulations are generally uncommon, but the potential for toxicity is increased at high mg per kg doses, especially in neonates and infants. Methyl and Propyl para-hydroxybenzoate (Parabens), Benzyl Alcohol, Sodium Benzoate, Benzoic Acid, and Propylene Glycol, among others, are some of the common pharmaceutical excipients that have reported side effects.
Pharmaceutical excipients are not always the inert substances that we presume. They are intolerant to an individual or, if not properly screened, can cause chemical changes in the drug, causing the side-effect. This can affect the demand for the excipient and is expected to act as a challenge for the Middle East & Africa pharmaceutical excipients market.
Post-COVID-19 Impact on Middle East & Africa Pharmaceutical Excipients Market
The pharmaceutical industry has been severely affected by the COVID-19 pandemic. Lockdowns imposed due to the epidemic have disrupted the supply of raw materials from manufacturing centers such as India and China. This slowed drug development and production, severely affecting companies that relied heavily on outsourcing. Initially, the entire pharmaceutical ecosystem was disrupted. In addition, regulatory agencies had to draft and draft new laws to ensure maximum patient safety after using drugs. After the shutdowns ended, the pharmaceutical industry gained steam, especially due to the demand for drugs such as hydroxychloroquine and Remdesivir, which showed positive results against COVID-19. The growing demand for these drugs boosted the turnover of some companies.
Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities and product launches, and strategic partnerships to improve the technology and test results involved in the pharmaceutical excipients market.
Recent Developments
- In February 2022, Kerry Group Plc., the world’s leading taste and Nutrition Company, announced that it had made two significant biotechnology acquisitions that have expanded its expertise, technology portfolio, and manufacturing capabilities. The company has announced that it has acquired the leading biotechnology Innovation Company, c-LEcta, and Mexican-based enzyme manufacturer, Enmex. c-LEcta is a leading biotechnology innovation company specializing in precision fermentation, optimized bio-processing, and bio-transformation. Also, Enmex is a well-established enzyme manufacturer based in Mexico, supplying multiple bio-process solutions for food, beverage, and animal nutrition markets. This has helped company to increase its revenue.
- 2022년 9월, 제약 및 건강보조식품 부형제 솔루션 분야의 중동 및 아프리카 리더인 DFE Pharma는 인도 하이데라바드에 우수 센터인 새로운 "Closer to the Formulator"(C2F)를 열었습니다. C2F는 제약 회사가 제약 개발의 모든 단계에 대한 전문 지식을 통해 개념에서 완제품까지의 시간을 단축하도록 도왔습니다. 이를 통해 회사는 진행 상황을 보여줄 수 있었습니다.
중동 및 아프리카 제약 보조제 시장 범위
중동 및 아프리카 제약 부형제 시장은 기능, 투여 형태, 투여 경로, 최종 사용자 및 유통 채널로 세분화됩니다. 세그먼트 간의 성장은 틈새 성장 포켓과 시장에 접근하고 핵심 응용 분야와 타겟 시장의 차이점을 파악하기 위한 전략을 분석하는 데 도움이 됩니다.
중동 및 아프리카 제약 보조제 시장, 기능성별
- 바인더 및 접착제
- 분해제
- 코팅재질
- 착색제
- 가용화제
- 풍미
- 감미료제
- 희석제
- 윤활제
- 버퍼
- 유화제
- 방부제
- 항산화제
- 흡착제
- 용매
- 완화제
- 글리덴츠
- 킬레이트제
- 소포제
- 기타
기능성을 기준으로 중동 및 아프리카 제약용 부형제 시장은 결합제 및 접착제, 붕괴제, 코팅제, 착색제, 용해제, 향미료, 감미료, 희석제, 윤활제, 완충액, 유화제, 방부제, 산화 방지제, 흡착제, 용매, 연화제, 글리덴트, 킬레이트제, 소포제 및 기타로 구분됩니다.
중동 및 아프리카 제약 보조제 시장, 투여 형태별
- 단단한
- 반고체
- 액체
중동 및 아프리카 제약용 부형제 시장은 투여 형태를 기준으로 고체, 반고체 및 액체로 구분됩니다.
중동 및 아프리카 제약 보조제 시장, 투여 경로별
- 경구용 부형제
- 국소 부형제
- 비경구적 보조제
- 기타 부형제
투여 경로를 기준으로 중동 및 아프리카 제약용 부형제 시장은 경구 제약용 부형제, 국소 제약용 부형제, 비경구 제약용 부형제 및 기타 부형제로 구분됩니다.
중동 및 아프리카 제약 보조제 시장, 최종 사용자별
- 제약 및 생물제약 회사
- 계약 제조자
- 연구기관 및 학계
- 기타
중동 및 아프리카 제약용 부형제 시장은 최종 사용자를 기준으로 제약 및 생물제약 회사, 계약 제조사, 연구 기관, 학계 등으로 구분됩니다.
중동 및 아프리카 제약 보조제 시장, 유통 채널별
- 직접 입찰
- 소매 판매
- 기타
중동 및 아프리카 제약용 부형제 시장은 유통 채널을 기준으로 직접 입찰, 소매 판매 및 기타로 구분됩니다.
중동 및 아프리카 제약 보조제 시장 지역 분석/통찰력
중동 및 아프리카 제약용 부형제 시장을 분석하고, 기능, 투여 형태, 투여 경로, 최종 사용자 및 유통 채널에 대한 시장 규모 정보를 제공합니다.
이 시장 보고서에서 다루는 국가는 남아프리카, 사우디 아라비아, UAE, 이스라엘, 쿠웨이트, 이집트, 중동 및 아프리카의 나머지 지역입니다.
- 2022년에는 GDP가 높은 가장 큰 소비자 시장에 주요 시장 참여자가 존재하기 때문에 중동 및 아프리카가 우세합니다. 남아프리카는 Healthcare IT의 기술 발전으로 인해 성장할 것으로 예상됩니다.
보고서의 국가 섹션은 또한 현재 및 미래 시장 추세에 영향을 미치는 국내 시장의 개별 시장 영향 요인과 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 중동 및 아프리카 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.
경쟁 환경 및 중동 및 아프리카 제약 보조제 시장 점유율 분석
중동 및 아프리카 제약 보조제 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, R&D 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 시험 파이프라인, 제품 승인, 특허, 제품 폭 및 호흡, 응용 프로그램 우세, 기술 수명선 곡선입니다. 위에 제공된 데이터 포인트는 중동 및 아프리카 제약 보조제 시장에 대한 회사의 초점과만 관련이 있습니다.
중동 및 아프리카 제약용 부형제 시장의 주요 기업으로는 Kerry Group plc., DFE Pharma, Cargill, Incorporated, Pfanstiehl, Colorcon, MEGGLE GmbH & Co. KG, Omya AG, Peter Greven GmbH & Co. KG, Ashland., Evonik, Dow 등이 있습니다.
연구 방법론: 중동 및 아프리카 제약 보조제 시장
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석 및 추정됩니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 기본(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 이 외에도 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 회사 시장 점유율 분석, 측정 표준, 중동 및 아프리카 대 지역, 공급업체 점유율 분석이 포함됩니다. 추가 문의 사항이 있는 경우 분석가에게 전화를 요청하십시오.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 FUNCTIONALITY LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
3.1 PESTEL
3.2 PORTER'S FIVE FORCES MODEL
3.3 INDUSTRIAL INSIGHTS:
4 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENT MARKET: REGULATIONS
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISE IN GENERIC DRUG PRODUCTION AND USES
5.1.2 THE SURGE IN DEMAND FOR EXCIPIENTS
5.1.3 TECHNOLOGICAL ADVANCEMENTS IN MULTIFUNCTIONAL EXCIPIENTS
5.1.4 RISING FOCUS ON ORPHAN DRUGS
5.2 RESTRAINTS
5.2.1 INCREASING REGULATORY STRINGENCY REGARDING THE APPROVAL OF DRUGS AND EXCIPIENTS
5.2.2 HIGH PRODUCTION COST
5.3 OPPORTUNITIES
5.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS
5.3.2 RISING DEMAND FOR EASE OF USE
5.3.3 RISING DISPOSABLE INCOME
5.3.4 INCREASING DEMAND FOR ALTERNATIVE ROUTES OF DELIVERY/DOSAGE FORMS
5.4 CHALLENGES
5.4.1 ASSOCIATED SIDE EFFECTS
5.4.2 SAFETY CONSIDERATION OF PHARMACEUTICAL EXCIPIENTS IN STORAGE & TRANSPORTATION
5.4.3 LACK OF NOVEL PHARMACEUTICAL PHARMACEUTICAL EXCIPIENTS
6 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY
6.1 OVERVIEW
6.2 BINDERS AND ADHESIVES
6.2.1 ORGANIC
6.2.2 INORGANIC
6.3 DISINTEGRANTS
6.3.1 ORGANIC
6.3.2 INORGANIC
6.4 COATING MATERIAL
6.4.1 ORGANIC
6.4.2 INORGANIC
6.5 COLORING AGENTS
6.5.1 ORGANIC
6.5.2 INORGANIC
6.6 SOLUBILIZERS
6.6.1 ORGANIC
6.6.2 INORGANIC
6.7 FLAVORS
6.7.1 ORGANIC
6.7.2 INORGANIC
6.8 SWEETENING AGENTS
6.8.1 ORGANIC
6.8.2 INORGANIC
6.9 DILUENTS
6.9.1 ORGANIC
6.9.2 INORGANIC
6.1 LUBRICANTS
6.10.1 ORGANIC
6.10.2 INORGANIC
6.11 BUFFERS
6.11.1 ORGANIC
6.11.2 INORGANIC
6.12 EMULSIFYING AGENTS
6.12.1 ORGANIC
6.12.2 INORGANIC
6.13 PRESERVATIVES
6.13.1 ORGANIC
6.13.2 INORGANIC
6.14 ANTIOXIDANTS
6.14.1 ORGANIC
6.14.2 INORGANIC
6.15 SORBENTS
6.15.1 ORGANIC
6.15.2 INORGANIC
6.16 SOLVENTS
6.16.1 ORGANIC
6.16.2 INORGANIC
6.17 EMOLLIENTS
6.17.1 ORGANIC
6.17.2 INORGANIC
6.18 GLIDENTS
6.18.1 ORGANIC
6.18.2 INORGANIC
6.19 CHELATING AGENTS
6.19.1 ORGANIC
6.19.2 INORGANIC
6.2 ANTIFOAMING AGENTS
6.20.1 ORGANIC
6.20.2 INORGANIC
6.21 OTHERS
7 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET, BY DOSAGE FORM
7.1 OVERVIEW
7.2 SOLID
7.2.1 PLANT
7.2.2 ANIMALS
7.2.3 SYNTHETIC
7.2.4 MINERALS
7.3 SEMI-SOLID
7.3.1 PLANT
7.3.2 ANIMALS
7.3.3 SYNTHETIC
7.3.4 MINERALS
7.4 LIQUID
7.4.1 PLANT
7.4.2 ANIMALS
7.4.3 SYNTHETIC
7.4.4 MINERALS
8 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET, BY ROUTE OF ADMINISTRATION
8.1 OVERVIEW
8.2 ORAL EXCIPIENTS
8.3 TOPICAL EXCIPIENTS
8.4 PARENTERAL EXCIPIENTS
8.5 OTHER EXCIPIENTS
9 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 DIRECT TENDER
9.2.1 COMPANY TENDER
9.2.2 TENDER THROUGH MARCH MERCHANDISER
9.3 RETAIL SALES
9.4 OTHERS
10 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET, BY END USER
10.1 OVERVIEW
10.2 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
10.3 CONTRACT FORMULATORS
10.4 RESEARCH ORGANIZATION
10.5 OTHERS
11 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION
11.1 MIDDLE EAST AND AFRICA
11.1.1 SOUTH AFRICA
11.1.2 U.A.E
11.1.3 SAUDI ARABIA
11.1.4 KUWAIT
11.1.5 EGYPT
11.1.6 ISRAEL
11.1.7 REST OF MIDDLE EAST AND AFRICA
12 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 DOW
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENTS
14.2 ROQUETTE FRÈRES.
14.2.1 COMPANY SNAPSHOT
14.2.2 COMPANY SHARE ANALYSIS
14.2.3 PRODUCT PORTFOLIO
14.2.4 RECENT DEVELOPMENTS
14.3 EVONIK
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENTS
14.4 THE LUBRIZOL CORPORATION
14.4.1 COMPANY SNAPSHOT
14.4.2 COMPANY SHARE ANALYSIS
14.4.3 PRODUCT PORTFOLIO
14.4.4 RECENT DEVELOPMENTS
14.5 BASF SE
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENTS
14.6 ASHLAND (2021)
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENTS
14.7 AVANTOR, INC.
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENTS
14.8 BENEO
14.8.1 COMPANY SNAPSHOT
14.8.2 PRODUCT PORTFOLIO
14.8.3 RECENT DEVELOPMENTS
14.9 CARGILL, INCORPORATED.
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENTS
14.1 CHEMIE TRADE
14.10.1 COMPANY SNAPSHOT
14.10.2 PRODUCT PORTFOLIO
14.10.3 RECENT DEVELOPMENTS
14.11 COLORCON
14.11.1 COMPANY SNAPSHOT
14.11.2 PRODUCT PORTFOLIO
14.11.3 RECENT DEVELOPMENTS
14.12 CRODA INTERNATIONAL PLC
14.12.1 COMPANY SNAPSHOT
14.12.2 REVENUE ANALYSIS
14.12.3 PRODUCT PORTFOLIO
14.12.4 RECENT DEVELOPMENTS
14.13 DFE PHARMA (SUBSIDIARY OF ROYAL FRIESLANDCAMPINA N.V)
14.13.1 COMPANY SNAPSHOT
14.13.2 REVENUE ANALYSIS
14.13.3 PRODUCT PORTFOLIO
14.13.4 RECENT DEVELOPMENTS
14.14 KERRY GROUP PLC.
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENTS
14.15 MEGGLE GMBH & CO. KG
14.15.1 COMPANY SNAPSHOT
14.15.2 PRODUCT PORTFOLIO
14.15.3 RECENT DEVELOPMENTS
14.16 OMYA AG
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENTS
14.17 PETER GREVEN GMBH & CO. KG
14.17.1 COMPANY SNAPSHOT
14.17.2 PRODUCT PORTFOLIO
14.17.3 RECENT DEVELOPMENTS
14.18 PFANSTIEHL
14.18.1 COMPANY SNAPSHOT
14.18.2 PRODUCT PORTFOLIO
14.18.3 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
표 목록
TABLE 1 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 2 MIDDLE EAST & AFRICA BINDERS AND ADHESIVES IN PHARMACEUTICAL EXCIPIENTS MARKETS, BY REGION, 2015-2029 (USD MILLION)
TABLE 3 MIDDLE EAST & AFRICA BINDERS AND ADHESIVES IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA DISINTEGRANTS IN PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION, 2015-2029 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA DISINTEGRANTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA COATING MATERIAL IN PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION, 2015-2029 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA COATING MATERIAL IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA COLORING AGENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION, 2015-2029 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA COLORING AGENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA SOLUBILIZERS IN PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION, 2015-2029 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA SOLUBILIZERS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA FLAVORS IN PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION, 2015-2029 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA FLAVORS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA SWEETENING AGENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION, 2015-2029 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA SWEETENING AGENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA DILUENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION, 2015-2029 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA DILUENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA LUBRICANTS IN PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION, 2015-2029 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA LUBRICANTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA BUFFERS IN PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION, 2015-2029 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA BUFFERS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA EMULSIFYING AGENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION, 2015-2029 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA EMULSIFYING AGENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA PRESERVATIVES IN PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION, 2015-2029 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA PRESERVATIVES IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA ANTIOXIDANTS IN PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION, 2015-2029 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA ANTIOXIDANTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA SORBENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION, 2015-2029 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA SORBENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA SOLVENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION, 2015-2029 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA SOLVENTS PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA EMOLLIENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION, 2015-2029 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA EMOLLIENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA GLIDENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION, 2015-2029 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA GLIDENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 36 MIDDLE EAST & AFRICA CHELATING AGENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION, 2015-2029 (USD MILLION)
TABLE 37 MIDDLE EAST & AFRICA CHELATING AGENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 38 MIDDLE EAST & AFRICA ANTIFOAMING AGENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION, 2015-2029 (USD MILLION)
TABLE 39 MIDDLE EAST & AFRICA ANTIFOAMING AGENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 40 MIDDLE EAST & AFRICA OTHERS IN PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION, 2015-2029 (USD MILLION)
TABLE 41 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET, BY DOSAGE FORM, 2015-2029 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA SOLID IN PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION, 2015-2029 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA SOLID IN PHARMACEUTICAL EXCIPIENTS MARKET, BY DOSAGE FORM, 2015-2029 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA SEMI-SOLID IN PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION, 2015-2029 (USD MILLION)
TABLE 45 MIDDLE EAST & AFRICA SEMI-SOLID IN PHARMACEUTICAL EXCIPIENTS MARKET, BY DOSAGE FORM, 2015-2029 (USD MILLION)
TABLE 46 MIDDLE EAST & AFRICA LIQUID IN PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION, 2015-2029 (USD MILLION)
TABLE 47 MIDDLE EAST & AFRICA LIQUID IN PHARMACEUTICAL EXCIPIENTS MARKET, BY DOSAGE FORM, 2015-2029 (USD MILLION)
TABLE 48 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET, BY ROUTE OF ADMINISTRATION, 2015-2029 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA ORAL EXCIPIENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION, 2015-2029 (USD MILLION)
TABLE 50 MIDDLE EAST & AFRICA TOPICAL EXCIPIENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION, 2015-2029 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA PARENTERAL EXCIPIENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION, 2015-2029 (USD MILLION)
TABLE 52 MIDDLE EAST & AFRICA OTHER EXCIPIENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION, 2015-2029 (USD MILLION)
TABLE 53 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET, BY DISTRIBUTION CHANNEL, 2015-2029 (USD MILLION)
TABLE 54 MIDDLE EAST & AFRICA DIRECT TENDER IN PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION, 2015-2029 (USD MILLION)
TABLE 55 MIDDLE EAST & AFRICA DIRECT TENDER IN PHARMACEUTICAL EXCIPIENTS MARKET, BY DISTRIBUTION CHANNEL, 2015-2029 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA RETAIL SALES IN PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION, 2015-2029 (USD MILLION)
TABLE 57 MIDDLE EAST & AFRICA OTHERS IN PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION, 2015-2029 (USD MILLION)
TABLE 58 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET, BY END USER, 2015-2029 (USD MILLION)
TABLE 59 MIDDLE EAST & AFRICA PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES IN PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION, 2015-2029 (USD MILLION)
TABLE 60 MIDDLE EAST & AFRICA CONTRACT FORMULATORS IN PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION, 2015-2029 (USD MILLION)
TABLE 61 MIDDLE EAST & AFRICA RESEARCH ORGANIZATION AND ACADEMICS IN PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION, 2015-2029 (USD MILLION)
TABLE 62 MIDDLE EAST & AFRICA OTHERS IN PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION, 2015-2029 (USD MILLION)
그림 목록
FIGURE 1 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET: MULTIVARIATE MODELLING
FIGURE 7 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET: SEGMENTATION
FIGURE 12 THE RISE IN GENERIC DRUG PRODUCTION AND TECHNOLOGICAL FOCUS ON PHARMACEUTICAL EXCIPIENTS IS DRIVING THE MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 THE BINDERS AND ADHESIVES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET IN 2022 & 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET
FIGURE 15 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET : BY FUNCTIONALITY, 2021
FIGURE 16 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET : BY FUNCTIONALITY, 2022-2029 (USD MILLION)
FIGURE 17 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET : BY FUNCTIONALITY, CAGR (2022-2029)
FIGURE 18 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET : BY FUNCTIONALITY, LIFELINE CURVE
FIGURE 19 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET: BY DOSAGE FORM, 2021
FIGURE 20 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET: BY DOSAGE FORM, 2022-2029 (USD MILLION)
FIGURE 21 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET: BY DOSAGE FORM, CAGR (2022-2029)
FIGURE 22 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET: BY DOSAGE FORM, LIFELINE CURVE
FIGURE 23 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 24 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
FIGURE 25 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 26 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 27 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 28 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 29 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 30 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 31 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET : BY END USER, 2021
FIGURE 32 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET : BY END USER, 2022-2029 (USD MILLION)
FIGURE 33 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET : BY END USER, CAGR (2022-2029)
FIGURE 34 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET : BY END USER, LIFELINE CURVE
FIGURE 35 MIDDLE EAST AND AFRICA PHARMACEUTICAL EXCIPIENTS MARKET: SNAPSHOT (2021)
FIGURE 36 MIDDLE EAST AND AFRICA PHARMACEUTICAL EXCIPIENTS MARKET: BY COUNTRY (2021)
FIGURE 37 MIDDLE EAST AND AFRICA PHARMACEUTICAL EXCIPIENTS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 38 MIDDLE EAST AND AFRICA PHARMACEUTICAL EXCIPIENTS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 39 MIDDLE EAST AND AFRICA PHARMACEUTICAL EXCIPIENTS MARKET: BY FUNCTIONALITY (2022-2029)
FIGURE 40 MIDDLE EAST & AFRICA PHARMACEUTICAL EXCIPIENTS MARKET: COMPANY SHARE 2021 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.